CIM
CPRX

Cambria Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Cambria Investment Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$741K Buy
29,918
+2,777
+10% +$66.2K 0.04% 281
2025
Q4 		$633K Buy
27,141
+5,424
+25% +$121K 0.04% 342
2025
Q3 		$428K Buy
21,717
+4,338
+25% +$89.2K 0.03% 382
2025
Q2 		$377K Sell
17,379
-482
-3% -$11.4K 0.03% 347
2025
Q1 		$433K Buy
+17,861
New +$402K 0.03% 255

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Cambria Investment Management's CPRX Position: Q1 2026 in Review

Cambria Investment Management increased its Catalyst Pharmaceutical (CPRX) stake by 10% in Q1 2026, buying an estimated $66.2K and bringing the position to 29,918 shares worth $741K. The position accounts for 0.04% of the portfolio, ranked #281.

Cambria Investment Management first reported a position in CPRX in Q1 2025 and has held it in 5 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Cambria Investment Management held 29,918 shares of Catalyst Pharmaceutical worth $741K as of Q1 2026.
  • Cambria Investment Management bought 2,777 Catalyst Pharmaceutical shares in Q1 2026, an estimated $66.2K.
  • Catalyst Pharmaceutical made up 0.04% of Cambria Investment Management's portfolio in Q1 2026, its #281 holding.
  • Cambria Investment Management first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 5 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Cambria Investment Management's 13F filing for Q1 2026, filed 15 May 2026.